Espra 40mg is an ulcer-healing drug, that inhibits gastric acid by blocking the proton-pump (Hydrogen-Potassium atpase enzyme system of the gastric perital cells Espra 40mg is used for the short-term treatment of gastric and duodenal ulcers and in gastro-oesophageal reflux disease with severe symptoms. Espra 40mg is also used in combination with antibacterials for the eradication of Helicobacter pylori.
Espra 40mg is primarily indicated in conditions like Gastric ulcer, Gastroesophageal reflux disease, NSAID-associated ulceration, Zollinger-ellison syndrome, and can also be given in adjunctive therapy as an alternative drug of choice in Pernicious anaemia and other macrocytic anaemias
Espra 40mg is contraindicated in conditions like Hypersensitivity to the drug
The severe or irreversible adverse effects of Espra 40mg, which give rise to further complications include Liver damage. The symptomatic adverse reactions produced by Espra 40mg are more or less tolerable and if they become severe, they can be treated symptomatically, these include Flatulence, Dizziness, Headache. Fatigue, Diarrhea, Myalgia, Constipation, Abdominal pain, Dry mouth, Blurred vision, Rashes, Pruritus, Malaise, Arthralgia, Nausea and vomiting, Musculoskeletal pain, Dry mouth, dizziness, subacute myopathy, athralgia
Espra 40mg should be given with caution in patients with renal impairment, liver disease, in pregnancy and in breast-feeding. Proton pump inhibitors may mask symptoms of gastric cancer, particular care is required in those whose symptoms change and in those over 45 years of age; the presence of gastric malignancy should be excluded before treatment
High Risk Groups
Drug should not be given to Paediatrics Pregnant Mothers, Geriatrics, and Neonates. If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies